CytomX Therapeutics (CTMX) Competitors $1.00 0.00 (0.00%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CTMX vs. DRRX, SELB, MEIP, RDHL, KMDA, DSGN, MNPR, INZY, ACIU, and AVIRShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include DURECT (DRRX), Selecta Biosciences (SELB), MEI Pharma (MEIP), RedHill Biopharma (RDHL), Kamada (KMDA), Design Therapeutics (DSGN), Monopar Therapeutics (MNPR), Inozyme Pharma (INZY), AC Immune (ACIU), and Atea Pharmaceuticals (AVIR). These companies are all part of the "medical" sector. CytomX Therapeutics vs. DURECT Selecta Biosciences MEI Pharma RedHill Biopharma Kamada Design Therapeutics Monopar Therapeutics Inozyme Pharma AC Immune Atea Pharmaceuticals DURECT (NASDAQ:DRRX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment. Which has more risk and volatility, DRRX or CTMX? DURECT has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Is DRRX or CTMX more profitable? CytomX Therapeutics has a net margin of 9.27% compared to DURECT's net margin of -187.80%. CytomX Therapeutics' return on equity of -27.44% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-187.80% -261.43% -66.98% CytomX Therapeutics 9.27%-27.44%5.78% Do analysts prefer DRRX or CTMX? DURECT currently has a consensus target price of $21.00, suggesting a potential upside of 1,490.91%. CytomX Therapeutics has a consensus target price of $5.77, suggesting a potential upside of 479.74%. Given DURECT's higher probable upside, analysts clearly believe DURECT is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in DRRX or CTMX? 28.0% of DURECT shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 4.3% of DURECT shares are owned by insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer DRRX or CTMX? In the previous week, DURECT and DURECT both had 1 articles in the media. CytomX Therapeutics' average media sentiment score of 1.45 beat DURECT's score of 0.93 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DURECT 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, DRRX or CTMX? CytomX Therapeutics has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$8.41M4.87-$27.62M-$0.95-1.39CytomX Therapeutics$119.57M0.65-$570K$0.204.98 Does the MarketBeat Community favor DRRX or CTMX? CytomX Therapeutics received 56 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 65.61% of users gave CytomX Therapeutics an outperform vote while only 64.36% of users gave DURECT an outperform vote. CompanyUnderperformOutperformDURECTOutperform Votes31664.36% Underperform Votes17535.64% CytomX TherapeuticsOutperform Votes37265.61% Underperform Votes19534.39% SummaryCytomX Therapeutics beats DURECT on 14 of the 17 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.58M$7.12B$5.36B$8.41BDividend YieldN/A8.77%5.22%4.20%P/E Ratio7.1116.06131.9317.57Price / Sales0.65258.281,440.1578.36Price / CashN/A50.1639.0633.56Price / Book-1.405.674.744.57Net Income-$570,000.00$151.16M$115.43M$225.42M7 Day Performance-7.81%-1.80%-0.86%-0.61%1 Month Performance-15.62%5.92%3.61%1.50%1 Year Performance-9.48%39.97%38.90%32.94% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.3778 of 5 stars$1.00flat$5.77+479.7%-10.6%$77.58M$119.57M7.11170Upcoming EarningsNews CoveragePositive NewsDRRXDURECT3.4071 of 5 stars$1.48+3.5%$21.00+1,318.9%-45.8%$45.94M$8.41M-2.4380Positive NewsSELBSelecta BiosciencesN/AN/AN/AN/A$136.76M$110.78M-4.0164Analyst ForecastGap DownHigh Trading VolumeMEIPMEI Pharma4.7529 of 5 stars$3.09+13.2%$7.00+126.9%-54.4%$18.19M$65.30M1.16100Analyst ForecastNews CoverageHigh Trading VolumeRDHLRedHill Biopharma1.2597 of 5 stars$8.35+1.8%N/A-97.3%$10.60M$6.53M0.00210KMDAKamada4.4466 of 5 stars$5.45+3.2%$14.50+166.1%+28.4%$313.27M$154.57M20.19360Short Interest ↓News CoverageHigh Trading VolumeDSGNDesign Therapeutics2.0664 of 5 stars$5.53+1.7%$7.00+26.6%+173.0%$312.42MN/A-6.1440Positive NewsMNPRMonopar Therapeutics3.872 of 5 stars$17.83+5.3%$22.00+23.4%+626.2%$311.74MN/A-7.7510Gap DownHigh Trading VolumeINZYInozyme Pharma3.2288 of 5 stars$4.78-0.2%$16.14+237.7%+54.9%$299.85MN/A-3.2750Upcoming EarningsShort Interest ↓ACIUAC Immune3.1306 of 5 stars$3.00-1.6%$12.00+300.0%+10.4%$296.70M$15.49M-4.17140Upcoming EarningsShort Interest ↓News CoveragePositive NewsAVIRAtea Pharmaceuticals3.753 of 5 stars$3.42+2.1%$6.88+101.2%+5.8%$288.04M$351.37M-1.6370Short Interest ↓ Related Companies and Tools Related Companies DURECT Competitors Selecta Biosciences Competitors MEI Pharma Competitors RedHill Biopharma Competitors Kamada Competitors Design Therapeutics Competitors Monopar Therapeutics Competitors Inozyme Pharma Competitors AC Immune Competitors Atea Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTMX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.